MA47932B1 - Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame - Google Patents

Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame

Info

Publication number
MA47932B1
MA47932B1 MA47932A MA47932A MA47932B1 MA 47932 B1 MA47932 B1 MA 47932B1 MA 47932 A MA47932 A MA 47932A MA 47932 A MA47932 A MA 47932A MA 47932 B1 MA47932 B1 MA 47932B1
Authority
MA
Morocco
Prior art keywords
antigen
tumor
relates
cell receptors
taa
Prior art date
Application number
MA47932A
Other languages
English (en)
Inventor
Claudia Wagner
Dominik Maurer
Leonie ALTEN
Sebastian Bunk
Mathias FERBER
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017106305.6A external-priority patent/DE102017106305A1/de
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA47932B1 publication Critical patent/MA47932B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des constructions de reconnaissance d'antigène contre des antigènes associés à une tumeur (TAA), en particulier contre un antigène de mélanome exprimé de manière préférentielle (PRAME). L'invention concerne en particulier de nouvelles molécules à base de récepteurs des lymphocytes T (TCR) qui sont sélectives et spécifiques dudit antigène exprimé par la tumeur. Le récepteur TCR de l'invention et les fragments de liaison à l'antigène associé à une tumeur (TAA) dérivés de celui-ci sont utiles pour le diagnostic, le traitement et la prévention de maladies cancéreuses exprimant l'antigène associé à une tumeur (TAA). L'invention concerne, en outre, des acides nucléiques codant pour les constructions de reconnaissance d'antigènes de l'invention, des vecteurs comprenant ces acides nucléiques, des cellules recombinantes exprimant les constructions de reconnaissance d'antigènes et des compositions pharmaceutiques comprenant les composés de l'invention.
MA47932A 2017-03-23 2018-03-23 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame MA47932B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762475329P 2017-03-23 2017-03-23
DE102017106305.6A DE102017106305A1 (de) 2017-03-23 2017-03-23 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
PCT/EP2018/057482 WO2018172533A2 (fr) 2017-03-23 2018-03-23 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame
EP18715559.3A EP3600409B1 (fr) 2017-03-23 2018-03-23 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame

Publications (1)

Publication Number Publication Date
MA47932B1 true MA47932B1 (fr) 2024-09-30

Family

ID=61899213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47932A MA47932B1 (fr) 2017-03-23 2018-03-23 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame

Country Status (31)

Country Link
US (2) US11236145B2 (fr)
EP (2) EP3600409B1 (fr)
JP (3) JP2020511152A (fr)
KR (2) KR20190132655A (fr)
CN (2) CN118852404A (fr)
AU (2) AU2018240501B2 (fr)
BR (1) BR112019019523A2 (fr)
CA (1) CA3056493A1 (fr)
CL (1) CL2019002645A1 (fr)
CO (1) CO2019011688A2 (fr)
CR (1) CR20190482A (fr)
DK (1) DK3600409T3 (fr)
ES (1) ES2986840T3 (fr)
FI (1) FI3600409T3 (fr)
HR (1) HRP20241228T1 (fr)
HU (1) HUE068640T2 (fr)
IL (2) IL269578B2 (fr)
LT (1) LT3600409T (fr)
MA (1) MA47932B1 (fr)
MD (1) MD3600409T2 (fr)
MX (2) MX2019011260A (fr)
MY (1) MY199084A (fr)
PE (1) PE20191493A1 (fr)
PH (1) PH12019502151A1 (fr)
PL (1) PL3600409T3 (fr)
PT (1) PT3600409T (fr)
RS (1) RS65924B1 (fr)
SG (1) SG11201908023YA (fr)
SI (1) SI3600409T1 (fr)
SM (1) SMT202400351T1 (fr)
TW (1) TWI799922B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173560A1 (fr) 2020-02-24 2021-09-02 Immatics US, Inc. Procédés de multiplication des cellules t pour le traitement du cancer et des malignités connexes
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
CA3081840A1 (fr) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. Compositions et procedes de production de lymphocytes t
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3670530A1 (fr) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Récepteurs de cellules t spécifiques de cd22 et thérapie par lymphocytes t adoptive pour le traitement des malignités des cellules b
WO2020172332A1 (fr) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques pour des néo-antigènes ras et leurs utilisations
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
WO2020191172A1 (fr) 2019-03-19 2020-09-24 Immatics US, Inc. Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation
EP3965818A4 (fr) * 2019-05-08 2023-05-31 Janssen Biotech, Inc. Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
WO2020243134A1 (fr) 2019-05-27 2020-12-03 Immatics US, Inc. Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
EP4061827A1 (fr) * 2019-11-18 2022-09-28 BioNTech SE Récepteurs de prame tcr et utilisations correspondantes
IL294988A (en) * 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022017435A1 (fr) * 2020-07-22 2022-01-27 信达生物制药(苏州)有限公司 SÉRIE DE BIOMARQUEURS DE SÉQUENCES CONSENSUS DANS UNE SÉQUENCE CDR3 DE CHAÎNE TCR-β ET LEUR APPLICATION
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
KR20230135589A (ko) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 Cd8 폴리펩타이드, 조성물 및 이의 사용 방법
EP4334361A1 (fr) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Protéines de liaison à l'antigène se liant de manière spécifique à prame
CA3225252A1 (fr) 2021-07-14 2023-01-19 Jordan JARJOUR Recepteurs de lymphocytes t modifies fusionnes a des domaines de liaison d'anticorps
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230190806A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of treating metastatic lesions and compositions thereof
CN113789304B (zh) * 2021-10-14 2023-03-31 深圳大学总医院 高亲和力tcr及其应用
CN113817044B (zh) * 2021-10-14 2023-10-13 深圳大学总医院 T细胞受体、相关工程化细胞及其应用
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4448108A1 (fr) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Traitement combiné de thérapie cellulaire adoptive et compositions associées
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
JP2025515603A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115073584B (zh) * 2022-05-07 2023-10-20 溧阳瑅赛生物医药有限公司 一种特异性识别prame抗原肽的tcr及其应用
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (fr) 2023-11-01 2025-05-08 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
WO2025096983A1 (fr) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène tpx2 et procédés d'utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (fr) 2000-02-08 2001-08-16 The Penn State Research Foundation Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
RU2578009C2 (ru) 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
JP2018510627A (ja) 2015-03-10 2018-04-19 レイデン ユニバーシティ メディカル センター メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
EP3067366A1 (fr) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Thérapie génique liée au récepteur de lymphocytes T combinés du cancer contre des épitopes restreints au CMH classe I ou classe I de l'antigène tumoral NY-ESO-1
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
CN106084036A (zh) 2015-11-02 2016-11-09 广州市香雪制药股份有限公司 识别prame抗原短肽的t细胞受体
CN106478809B (zh) 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr
CN106519019B (zh) 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
CN106699874B (zh) 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
EP3472208B9 (fr) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH Récepteurs de lymphocytes t et leurs utilisations
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) * 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten

Also Published As

Publication number Publication date
ES2986840T3 (es) 2024-11-12
EP3600409A2 (fr) 2020-02-05
MY199084A (en) 2023-10-12
LT3600409T (lt) 2024-09-10
HUE068640T2 (hu) 2025-01-28
IL310552A (en) 2024-03-01
EP4450087A2 (fr) 2024-10-23
IL269578A (en) 2019-11-28
PL3600409T3 (pl) 2024-10-21
JP7787119B2 (ja) 2025-12-16
TW202208420A (zh) 2022-03-01
CA3056493A1 (fr) 2018-09-27
BR112019019523A2 (pt) 2020-04-22
US20180273602A1 (en) 2018-09-27
IL269578B2 (en) 2024-07-01
RS65924B1 (sr) 2024-10-31
EP3600409B1 (fr) 2024-08-14
PE20191493A1 (es) 2019-10-21
AU2018240501B2 (en) 2025-04-10
IL310552B2 (en) 2026-04-01
CN110494160B (zh) 2024-06-25
CN110494160A (zh) 2019-11-22
MX2023003463A (es) 2023-04-19
JP2026021299A (ja) 2026-02-10
US20220098270A1 (en) 2022-03-31
KR20240151870A (ko) 2024-10-18
SG11201908023YA (en) 2019-10-30
PH12019502151A1 (en) 2020-06-29
AU2018240501A1 (en) 2019-10-31
EP4450087A3 (fr) 2025-01-08
KR20190132655A (ko) 2019-11-28
AU2025202086A1 (en) 2025-04-10
CR20190482A (es) 2020-01-07
IL310552B1 (en) 2025-12-01
IL269578B1 (en) 2024-03-01
JP2020511152A (ja) 2020-04-16
JP2023088973A (ja) 2023-06-27
MD3600409T2 (ro) 2024-11-30
SMT202400351T1 (it) 2024-11-15
FI3600409T3 (fi) 2024-09-03
SI3600409T1 (sl) 2024-10-30
CL2019002645A1 (es) 2019-12-13
DK3600409T3 (da) 2024-09-09
TWI799922B (zh) 2023-04-21
HRP20241228T1 (hr) 2024-11-22
US11236145B2 (en) 2022-02-01
CN118852404A (zh) 2024-10-29
PT3600409T (pt) 2024-09-13
MX2019011260A (es) 2019-12-05
CO2019011688A2 (es) 2020-02-28

Similar Documents

Publication Publication Date Title
MA47932B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame
MA49236B1 (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CO2019006914A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
Ghiringhelli et al. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy
SA520420526B1 (ar) Caix، بروتينات ربط متعددة النوعية تستهدف أوano1،أو ميسوثيلين، أوtrop2،أوcea، أو كلاودين-18.2
NZ777032A (en) Anti-nkg2a antibodies and uses thereof
MY196179A (en) T Cell Receptors Specific for the NY-ESO-1 Tumor Antigen-Hla-A*02 Complex
MA45309B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MA43330A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
PE20171790A1 (es) Anticuerpos anti-ceacam6 y sus usos
PH12022551857A1 (en) Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
CL2021001564A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407)
CR20200607A (es) INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551)
MX2019012226A (es) Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer.
AR113834A1 (es) Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
Jimbo et al. Induction of leukemia‐specific antibodies by immunotherapy with leukemia‐cell‐derived heat shock protein 70
EA202090712A1 (ru) Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением
CL2020002857A1 (es) Nuevos péptidos (seq id no: 146) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096)
CL2019001537A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
EA201991151A1 (ru) Новые т-клеточные рецепторы и иммунотерапия с их применением